AltruBio Inc.: Clinical Trials

3 completed, 1 active not recruiting, 1 terminated. 3 Phase 1, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	3	Completed 3
Phase 2	2	Active not recruiting 1, Terminated 1

Follow AltruBio Inc.: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants ALTB-268, Placebo - Ulcerative Colitis (UC)	Phase 1	Completed	AltruBio Inc.	24	2025-11-17	2026-10-29
Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics ALTB-268 - Ulcerative Colitis	Phase 2	Active not recruiting	AltruBio Inc.	50	2023-12-04	2026-05-05
A First-In-Human SAD and MAD Study to Evaluate the Safety, Tolerability, PK and PD of SC Administered ALTB-268 in Healthy Volunteers ALTB-268, Placebo - Healthy Volunteers	Phase 1	Completed	AltruBio Inc.	56	2023-01-17	2024-02-06
Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refractory Acute Graft-versus-host Disease Neihulizumab (ALTB-168) - Steroid-refractory Acute Graft-versus-Host Disease, Treatment-refractory Acute Graft-versus-Host Disease	Phase 1	Completed	AltruBio Inc.	37	2018-05-31	2023-01-19
Efficacy&Safety of ALTB-168 in Patients With Moderate to Severe Active,Anti-TNF Alpha and/or Anti-integrin Refractory UC ALTB-168 - Ulcerative Colitis	Phase 2	Terminated	AltruBio Inc.	24	2018-05-04	2024-01-05

Conditions studied

Colitis, Ulcerative (3)

Countries

United States (5)  ·  Puerto Rico (2)

Top investigators

Shih-Yao Lin, MD, PhD (2)  ·  Daniel Dickerson, MD (1)  ·  David Lin, MD, PhD (1)  ·  David T Rubin, MD (1)  ·  Paul Martin, MD (1)